Report published October 6, 2026
Moderna She Wrote: BTIG Technical Strategy on MRNA Inflection & Biotech Support Levels
BTIG · October 6, 2026
Moderna is exhibiting a key negative reversal day after surging nearly 600% YTD, triggering short-term breakdowns in biotech ETFs XBI and IBB toward their 200 DMAs. Meanwhile, despite new S&P 500 highs, underlying breadth, rate, and credit cross-currents warrant caution, while Utilities offer near-term upside.
Read the full report
An account opens the rest.
A card is required to start full-report access. Subscription terms apply.
Finvaulta summarizes BTIG's analysis. Attribute opinions, forecasts, time-sensitive values, and chronology to the issuer and report date; do not treat this page as an independent verification or a current market-data source.
Key Takeaways
- 1.Moderna (MRNA) is staging a key reversal off new highs after surging nearly 600% YTD, marking a likely negative inflection point that threatens biotech momentum.
- 2.The SPDR Biotech ETF (XBI) is breaking short-term support with downside risk toward August lows around $144 and potentially its 200 DMA around $139, which would offer a buyable dip.
- 3.Despite the S&P 500 breaking out to new all-time highs, conflicting cross-currents in breadth, interest rates, and credit indicate the breakout may fail to sustain momentum.
Table of Contents
- WHAT YOU SHOULD KNOW:
Report data
XBI US Equity (State Street SPDR S&P Biotech ETF) Daily 200 DMA
| Metric | Estimate | Context |
|---|---|---|
| Moderna YTD return | 590% | Second best performing stock in S&P 500 YTD |
| Sandisk YTD return | 617% | Best performing stock in S&P 500 YTD |
| XBI 200 DMA support price level | 139 USD | Support level that would likely prove buyable following a shakeout |
| XBI August low price level | 144 USD | Initial downside support level for XBI |
| IBB initial support level | 200 USD | Initial support level as uptrend breaks |
Reports in this series
Technical Strategy is shown in chronological order through this edition, published on October 6, 2026.
Part of the Technical Strategy series — view all 15 editions
Looking for the latest edition? SOX's Gain = AAPL's Pain(1) (Oct 19, 2026)
Access the full report
And others from the leading tier 1 banks.
Create an account to browse previews. A card is required to start full-report access; subscription terms apply.